FDA — authorised 26 October 2004
- Application: NDA021468
- Marketing authorisation holder: TAKEDA PHARMS USA
- Status: supplemented
🇺🇸 LANTHANUM CARBONATE in United States
FDA authorised LANTHANUM CARBONATE on 26 October 2004
Marketing authorisations
FDA — authorised 11 August 2017
- Application: ANDA090978
- Marketing authorisation holder: NATCO PHARMA LTD
- Status: supplemented
FDA — authorised 24 January 2022
- Application: ANDA206868
- Marketing authorisation holder: INVAGEN PHARMS
- Local brand name: LANTHANUM CARBONATE
- Indication: TABLET, CHEWABLE — ORAL
- Status: approved
FDA — authorised 27 January 2022
- Application: ANDA090977
- Marketing authorisation holder: BARR
- Status: approved
FDA — authorised 13 March 2025
- Application: ANDA202329
- Marketing authorisation holder: ALKEM LABS LTD
- Status: approved
FDA
- Status: approved
LANTHANUM CARBONATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is LANTHANUM CARBONATE approved in United States?
Yes. FDA authorised it on 26 October 2004; FDA authorised it on 11 August 2017; FDA authorised it on 24 January 2022.
Who is the marketing authorisation holder for LANTHANUM CARBONATE in United States?
TAKEDA PHARMS USA holds the US marketing authorisation.